What happens when you take carvedilol with st. john's wort?
Carvedilol is a non-selective beta-blocker with additional alpha-1 blocking activity, prescribed mainly for heart failure with reduced ejection fraction, hypertension, and post-heart-attack protection. Unlike simpler beta-blockers, carvedilol has a complex metabolism: it is broken down in the liver predominantly by CYP2D6 and CYP2C9, with secondary contributions from CYP3A4, CYP1A2, CYP2C19, and CYP2E1. It is also a substrate of P-glycoprotein, an efflux transporter that affects how much drug crosses gut and brain barriers.
St. John's Wort (Hypericum perforatum) contains hyperforin, which binds the pregnane X receptor in liver and intestine and switches on the genes that encode CYP3A4, CYP1A2, CYP2C9, CYP2C19, and P-glycoprotein. Because carvedilol depends on several of these enzymes, regular use of St. John's Wort for more than 10 days accelerates carvedilol clearance and lowers its plasma concentrations. The result is a weakened beta-blocker effect, with potential for loss of blood pressure control, reduced heart rate slowing, and in heart failure patients, partial loss of the survival-improving effect that justified the prescription.
Direct pharmacokinetic studies of carvedilol with St. John's Wort have not been published, but the mechanism is well established for many other CYP3A4 and CYP2C9 substrates including verapamil, digoxin, simvastatin, and warfarin, all of which show 40 to 80 percent drops in exposure when co-administered with the herb.
Why is this important?
Carvedilol in heart failure is not a comfort drug. Trials including COPERNICUS and CAPRICORN have shown that adequate carvedilol therapy reduces all-cause mortality and hospitalizations. Sub-therapeutic plasma levels, the predictable result of St. John's Wort co-administration, undermine that survival benefit.
In hypertension and post-MI patients, the consequences are smaller in any single day but real over time. Poorer blood pressure control raises stroke and coronary risk; weaker beta-blockade post-MI increases recurrence risk.
St. John's Wort users tend not to disclose the supplement to their cardiologist, partly because it is sold over the counter as a mood supplement and partly because patients do not always realize an herbal product can change how a heart drug works. Pharmacists may not know either, because the supplement is bought in grocery stores and health food shops outside the pharmacy.
The induction effect builds over about 10 to 14 days and persists for a similar time after stopping. That slow timeline can make the interaction hard to spot in routine clinical follow-up; a patient may simply seem to need a dose increase, and the cause is missed.
What should you do?
If you are on carvedilol, do not start St. John's Wort. Tell your cardiologist or primary care provider about every supplement and herbal product you currently take, especially mood-support, weight-loss, and bodybuilding stacks, which sometimes contain St. John's Wort or other CYP inducers under unfamiliar names.
If you are already taking both, raise it at your next visit. Do not stop St. John's Wort abruptly without discussing it, especially if you started it for low mood; a structured taper and plan for the underlying mood condition is preferable. Your cardiologist may want to monitor blood pressure and heart rate more closely during the two-week washout, because as enzyme induction fades, your effective carvedilol exposure rises again, and a dose that was right under the influence of St. John's Wort may now be too high.
If carvedilol seems less effective than it used to be, run through every supplement you take with your prescriber and pharmacist. CYP inducers besides St. John's Wort include rifampin, certain antiepileptics, and chronic heavy alcohol use. Identifying and removing the inducer is usually preferred over raising the carvedilol dose, because the underlying disease has not changed.
If you must keep both, accept that this requires close monitoring. Home blood pressure logs, more frequent clinic visits, and in some heart failure patients, BNP or echo monitoring to ensure adequate beta-blockade may be appropriate.
Which specific products are affected?
Carvedilol is sold as Coreg (immediate release) and Coreg CR (controlled release), along with many generics. Both formulations are affected by the same enzyme-induction mechanism, though the CR form's slow release may produce somewhat smoother dips rather than sharp drops.
St. John's Wort is sold under dozens of brand names as capsules, tablets, tinctures, and teas. Most clinical interaction data comes from standardized extracts containing 0.3 percent hypericin or 3 to 6 percent hyperforin. Low-hyperforin preparations are theoretically safer but are not reliably labeled, so the prudent assumption is that any St. John's Wort product induces CYP enzymes.
Other beta-blockers with complex CYP metabolism, including metoprolol (CYP2D6) and propranolol (CYP1A2, CYP2C19, CYP2D6), are also affected by St. John's Wort to varying degrees. Atenolol, which is mostly excreted unchanged in urine, has a smaller CYP-induction concern but P-glycoprotein effects could still matter.
The bottom line
St. John's Wort accelerates the breakdown of carvedilol by inducing the liver enzymes and intestinal transporters that handle the drug. The result is reduced carvedilol exposure and weaker beta-blockade, which is especially concerning in heart failure patients where adequate carvedilol therapy improves survival. Do not start St. John's Wort while on carvedilol; if you are already on both, talk to your cardiologist before changing anything, and expect close monitoring during any taper.